Project Grant R01CA316043
Award Date 7/20/26
Completion Date 6/30/31
Dollars Obligated $669K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded the Regents of the University of Michigan $669,278 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop microbial-based cancer therapeutics engineered to deliver localized immune activation while minimizing systemic toxicity. The research focuses on nonpathogenic, tumor-tropic E. coli engineered to display membrane-anchored cytokines, specifically decoy-resistant...
- The National Cancer Institute awarded the Regents of the University of Michigan $646,920 on March 11, 2026, under the Cancer Treatment Research program (CFDA 93.395, Assistance Listing) to conduct research on novel multi-targeted therapeutic strategies targeting T-cell lymphomas and their microenvironment. The funded work addresses chemotherapy-resistant T-cell lymphomas, where current treatments produce poor durable responses and clinical trial participation remains standard care. The...
- The National Cancer Institute awarded the Regents of the University of Michigan $646,671 under the Cancer Treatment Research program (CFDA 93.395) on May 15, 2026, to identify and validate payload candidates that maximize multiple immune-activation mechanisms in high-avidity low-affinity antibody-drug conjugates (ADCs) for combination immunotherapy in cancer treatment. The research addresses a critical gap in ADC development: existing mouse syngeneic models show poor sensitivity to ADC payloads,...
- The National Cancer Institute awarded the University of Massachusetts $832,936 under the Cancer Treatment Research program (CFDA 93.395) on June 26, 2026, to develop and evaluate dual-adjuvant, dual-delivery nanoparticle-based cancer vaccines. The research centers on a "prime-pull" vaccination approach that delivers nanoparticles both to lymph nodes for immune priming and to tumors to overcome the immunosuppressive tumor microenvironment. The nanoparticles incorporate two synergistic...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $699,794 on August 25, 2026, under the Cancer Treatment Research program (CFDA 93.395) to modulate the tumor microenvironment and enhance nanoparticle delivery to cancer cells. The project addresses limited nanoparticle efficacy in cancer therapies caused by nonspecific uptake in the mononuclear phagocyte system and interception by tumor-resident macrophages, which results in median tumor uptake of under 1...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc., $454,109 on July 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and test a novel approach for reprogramming tumor-associated macrophages using theranostic nanoparticles combined with radiation therapy to stimulate the body's immune system to treat cancer. Preliminary results demonstrate that nanoparticles combined with radiation can reprogram pro-tumor macrophages into an anti-tumor phenotype...
- The National Cancer Institute awarded Regents of the University of Michigan $660,808 on April 7, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate tissue-resident memory T cell responses in melanoma patients and their durability following immunotherapy treatment. The work will examine how tissue-resident memory T cells with high interferon gamma expression (TRM-IFNG), established at the time of primary melanoma diagnosis, are recalled and expanded to mediate...
- The National Institutes of Health National Cancer Institute awarded the Regents of the University of Michigan $571,735 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396, Assistance Listing R01CA312636). The award funds research into mechanisms by which collagen extracellular matrix disruption potentiates anti-glioma immune responses. The project combines collagen inhibition with immune-stimulatory gene therapy—specifically AD-HSV1-TK to increase tumor antigen release and...
- The National Cancer Institute awarded the Regents of the University of Michigan $646,285 on July 9, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the role of solute carrier family members in dendritic cell-mediated tumor immunity and immunotherapy response. The project examines how solute carrier (SLC) transporters—a superfamily of over 400 nutrient and metabolite transporters—regulate dendritic cell maturation and function within the tumor microenvironment, with...
- The National Cancer Institute awarded the University of Georgia Research Foundation $618,236 on March 24, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop calcium nanoparticles that enhance radio-immunotherapy by improving dendritic cell infiltration into tumors and migration to tumor-draining lymph nodes. The project focuses on surface-engineered calcium nanoparticles (ACANPs) designed to selectively deliver calcium into circulating conventional dendritic cells type...